

Supplementary Materials: FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer

Hsi-Hsien Hsu, Wei-Wen Kuo, Hui-Nung Shih, Sue-Fei Cheng, Ching-Kuo Yang, Ming-Cheng Chen, Chuan-Chou Tu, Vijaya Padma Viswanadha, Po-Hsiang Liao and Chih-Yang Huang









Figure S1. Nude mice weight changed after tumor cells injection. **(A)** The nude mouse weight was measured in five different groups: the LoVo cell group as the LoVo control group, the LoVo scrambled group treated with miR-agomir NC, the LoVo OXA group, the LoVo mimic group, and the LoVo mimic OXA group treated with or without OXA, miR-31-5p agomir, or both, administered every 3 days from day 0 to 15. **(B)** The nude mouse weight was measured in five different groups: the OR-LoVo cell group as the OR-LoVo control group, the OR-LoVo scrambled group treated with miR-antagomir NC, the OR-LoVo OXA group, the OR-LoVo inhibitor group, and the OR-LoVo inhibitor OXA group treated with or without OXA, miR-31-5p antagomir, or both, administered every 3 days from day 0 to 15.


For the western blotting data we used ImageQuant LAS 4000 mini (GE Healthcare Life Sciences), the readings/intensity ratio of each band we used standard/ exposed 20 second.




FOXC1



FOXC1



HDAC1



FOXC1



FOXC1

